Potential γ-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: A pharmacokinetic simulation-based evaluation

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 5, 2006, Pages 657-681

  Bhattacharya, Indranil ^a   Boje, Kathleen M K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

hydroxybutyric acid; Drug interaction; Nonlinear pharmacokinetics; Pharmacokinetic simulations; Pharmacokinetics; Salicylic acid

Indexed keywords

4 HYDROXYBUTYRIC ACID; MONOCARBOXYLATE TRANSPORTER; PROBENECID; SALICYLIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INHIBITION; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG TRANSPORT; HYPNOSIS; MATHEMATICAL COMPUTING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SEDATION; SIMULATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CARRIER PROTEINS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDROXYBUTYRATES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PILOT PROJECTS; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY; REFLEX; REPRODUCIBILITY OF RESULTS; SALICYLIC ACID;

EID: 33748668794     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9029-x     Document Type: Article

References (37)

1. R. H. Roth. Formation and regional distribution of gamma-hydroxybutyric acid in mammalian brain. Biochem. Pharmacol. 19:3013-3019 (1970).
2. T. Nelson, E. Kaufman, J. Kline, and L. Sokoloff. The extraneural distribution of gamma-hydroxybutyrate. J. Neurochem. 37:1345-1348 (1981).
3. J. E. Dyer. Gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am. J. Emerg. Med. 9:321-324 (1991).
4. J. E. Dyer, B. Roth, and B. A. Hyma. Gamma-hydroxybutyrate withdrawal syndrome. Ann. Emerg. Med. 37:147-153 (2001).
5. M. S. Okun, L. A. Boothby, R. B. Bartfield, and P. L. Doering. GHB: an important pharmacologic and clinical update. J. Pharm. Pharm. Sci. 4:167-175 (2001).
6. K. L. Nicholson and R. L. Balster. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 63:1-22 (2001).
7. J. T. Lettieri and H. L. Fung. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J. Pharmacol. Exp. Ther. 208:7-11 (1979).
8. N. R. Saunders, M. D. Habgood, and K. M. Dziegielewska. Barrier mechanisms in the brain, I. Adult brain. Clin. Exp. Pharmacol. Physiol. 26:11-19 (1999).
9. W. M. Pardridge. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 17:713-731 (1997).
10. G. Lee, S. Dallas, M. Hong, and R. Bendayan. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53:569-596 (2001).
11. I. Bhattacharya and K. M. Boje. GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier. J. Pharmacol. Exp. Ther. 311:92-98 (2004).
12. R. M. Echols, A. Heyd, B. J. O'Keeffe, and P. Schacht. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex. Transm. Dis. 21:345-352 (1994).
13. M. H. Augenbraun and R. Rolfs. Treatment of syphilis, 1998: nonpregnant adults. Clin. Infect. Dis. 28 Suppl 1:S21-28 (1999).
14. D. Pao, B. T. Goh, and J. S. Bingham. Management issues in syphilis. Drugs 62:1447-1461 (2002).
15. H. W. Haverkos. Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. J. Subst. Abuse Treat. 8:269-275 (1991).
16. L. Y. Hwang, M. W. Ross, C. Zack, L. Bull, K. Rickman, and M. Holleman. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. Clin. Infect. Dis. 31:920-926 (2000).
17. M. Clinical Pharmacology. Valproic Acid http://cp.gsm.com/.
18. B. A. Wroblewski, A. B. Joseph, J. Kupfer, and K. Kalliel. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj. 11:37-47 (1997).
19. G. Rosenberg. Brain Fluids and Metabolism. Oxford University Press, New York, 1990, pp. 15-53.
20. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
21. J. L. Coolens, H. Van Baelen, and W. Heyns. Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J. Steroid Biochem. 26:197-202 (1987).
22. M. A. Gonzalez, T. N. Tozer, and T. T. Chang. Nonlinear tissue disposition: salicylic acid in rat brain. J. Pharm. Sci. 64:99-103 (1975).
23. J. Hirate, Y. Kato, I. Horikoshi, S. Nagase, and C. T. Ueda. Further observations on the disposition characteristics of salicylic acid in analbuminemic rats. Biopharm. Drug Dispos. 10:299-309 (1989).
24. T. L. Yue and D. R. Varma. Pharmacokinetics, metabolism and disposition of salicylate in protein-deficient rats. Drug Metab. Dispos. 10:147-152 (1982).
25. B. M. Emanuelsson and L. K. Paalzow. Dose-dependent pharmacokinetics of probenecid in the rat. Biopharm. Drug Dispos. 9:59-70 (1988).
26. T. Terasaki, S. Takakuwa, S. Moritani, and A. Tsuji. Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. J. Pharmacol. Exp. Ther. 258:932-937 (1991).
27. E. E. Kaufman, T. Nelson, C. Goochee, and L. Sokoloff. Purification and characterization of an NADP+-linked alcohol oxido-reductase which catalyzes the interconversion of gamma-hydroxybutyrate and succinic semialdehyde. J. Neurochem. 32:699-712 (1979).
28. E. E. Kaufman and T. Nelson. Kinetics of coupled gamma-hydroxybutyrate oxidation and D-glucuronate reduction by an NADP+-dependent oxidoreductase. J. Biol. Chem. 256:6890-6894 (1981).
29. N. J. Giarman and R. H. Roth. Differential estimation of gamma-butyrolactone and gamma-hydroxybutyric acid in rat blood and brain. Science 145:583-584 (1964).
30. J. M. Perel, M. Levitt, and D. L. Dunner. Plasma and cerebrospinal fluid probenecid concentrations as related to accumulation of acidic biogenic amine metabolites in man. Psychopharmacologia 35:83-90 (1974).
31. L. A. Borgen, R. A. Okerholm, A. Lai, and M. B. Scharf. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J. Clin. Pharmacol. 44:253-257 (2004).
32. K. S. Kalasinsky, M. M. Dixon, G. A. Schmunk, and S. J. Kish. Blood, brain, and hair GHB concentrations following fatal ingestion. J. Forensic Sci. 46:728-730 (2001).
33. Y. Deguchi, K. Nozawa, S. Yamada, Y. Yokoyama, and R. Kimura. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. J. Pharmacol. Exp. Ther. 280:551-560 (1997).
34. S. H. Dromgoole and D. E. Furst. Salicylates. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.) Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. Applied Therapeutics, Inc, Vancouver, Washington, 1994, pp. 32-34.
35. R. Roth and N. Giarman. Gamma-butyrolactone and gamma-hydroxybutyric acid-I. Distribution and metabolism. Biochem. Pharmacol. 15:1333-1348 (1966).
36. B. E. Enerson and L. R. Drewes. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci. 92:1531-1544 (2003).
37. M. E. Morris, K. Hu, and Q. Wang. Renal clearance of gamma-hydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy. J. Pharmacol. Exp. Ther. 313:1194-1202 (2005).